	US 12,275,723 B2
	Compounds and uses thereof
Matthew Lucas, Lexington, MA (US); Bertrand Le Bourdonnec, Northborough, MA (US); Iwona Wrona, Sharon, MA (US); Bhaumik Pandya, Bedford, MA (US); Parcharee Tivitmahaisoon, Boston, MA (US); Kerem Ozboya, Cambridge, MA (US); Benjamin Vincent, Cambridge, MA (US); Daniel Tardiff, Arlington, MA (US); Jeff Piotrowski, Somerville, MA (US); Eric Solis, Milford, MA (US); Robert Scannevin, Hopkinton, MA (US); Chee-Yeun Chung, Brookline, MA (US); Rebecca Aron, Cambridge, MA (US); and Kenneth Rhodes, Belmont, MA (US)
Assigned to JANSSEN PHARMACEUTICA NV, Beerse (BE)
Filed by JANSSEN PHARMACEUTICA NV, Beerse (BE)
Filed on Sep. 27, 2023, as Appl. No. 18/373,702.
Application 18/373,702 is a continuation of application No. 16/758,495, granted, now 11,873,298, previously published as PCT/US2018/057339, filed on Oct. 24, 2018.
Claims priority of provisional application 62/662,424, filed on Apr. 25, 2018.
Claims priority of provisional application 62/576,591, filed on Oct. 24, 2017.
Prior Publication US 2024/0124435 A1, Apr. 18, 2024
Int. Cl. C07D 413/14 (2006.01); C07D 271/07 (2006.01); C07D 413/04 (2006.01); C07D 413/10 (2006.01); C07D 417/04 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 487/10 (2006.01)

CPC C07D 413/14 (2013.01) [C07D 271/07 (2013.01); C07D 413/04 (2013.01); C07D 413/10 (2013.01); C07D 417/04 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 487/10 (2013.01)]

16 Claims

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.